CD83 and neoplasm: Additionally, we also observed a significant increase in the total percentage of mature DCs (CD11c+ MHCII+ CD83+) both within the tumor (Fig. 3C) and the DLNs (Fig. 3E) in comparison to groups receiving PBS or MRF alone.